-
T cell activation + checkpoint inhibition: the 6-month survival rate of triple immunotherapy for glioblastoma multiforme (GBM) is 80%!
Time of Update: 2019-11-07
November 7, 2019 / Biovalley BIOON / -- new diagnosis of evaluation of triple immunotherapy (ino-5401, ion-9012, libtayo) was announced at the 2019 annual meeting of cancer immunotherapy Society (SITC
-
The world's first all human heavy chain antibody entering the clinical research stage: hbm4003, a platinum medicine, was successfully used in the first patient in Australia
Time of Update: 2019-11-06
November 6, 2019 / Biovalley BIOON / -- and platinum medicine announced that their new generation of all human anti-CTLA-4 antibody hbm4003 has launched the first global clinical trial for patients wi
-
Science subjournal: rotavirus vaccine is expected to overcome resistance to immunocheckpoint blocking therapy
Time of Update: 2019-11-04
November 4, 2019 / Biogen / - -- from influenza vaccines to vaccines that help prevent varicella and measles, many vaccines are widely used to prevent infectious diseases In a new study, French resear
-
Progress in tumor immunosuppression
Time of Update: 2019-11-03
Recently, Wan Xiaochun, a researcher of protein and cell medicine research center of Shenzhen Institute of advanced technology, Chinese Academy of Sciences, and his research team have made new progres
-
Great news! Baiji Shenzhou announced the establishment of a global cancer strategic partnership with Amgen
Time of Update: 2019-11-01
November 1, 2019 / BIOON / -- Baiji Shenzhou (NASDAQ (8292.3602, - 11.62, - 0.14%) code: bgne; Hong Kong stock exchange code: 06160) and Amgen (NASDAQ Code: AMGN) today announced a global cancer strat
-
Sutro has published the first phase clinical results of its ADC products against ovarian cancer
Time of Update: 2019-10-30
Sutro biopharma, located in San Francisco, California, USA, is a research, development and production enterprise of tumor drugs whose products are in clinical stage The company today released data on
-
Report: the global ovarian cancer treatment market will reach 6.7 billion US dollars in 2028!
Time of Update: 2019-10-29
October 29, 2019 / bioun / -- global data, a global well-known market research company, released the latest research forecast that the global ovarian cancer market will have a market value of US $1.8
-
First line immunotherapy for stage 4 lung cancer! AstraZeneca imfinzi 2 schemes were successful in phase III clinical trials, which significantly delayed disease progression!
Time of Update: 2019-10-29
October 29, 2019 / BIOON / -- AstraZeneca recently announced the positive progression free survival (PFS) results of Poseidon in the phase III clinical study of PD-L1 tumor immunotherapy, i.e immunoth
-
Bispecific antibody! Merus, a partner of pioneer pharmaceutical industry, announced the strong therapeutic effect data of HER2 / 3 antibody mcla-128 on NRG1 fusion cancer!
Time of Update: 2019-10-28
October 28, 2019 / BIOON / -- merus, partner of Simcere, recently announced the preliminary clinical data of NRG1 fusion cancer patients who received the treatment of dual antibody candidate drug mcla
-
Melanoma immunotherapy! Opdivo four week protocol is approved by European Union for adjuvant treatment of patients with lymph node involvement or metastasis
Time of Update: 2019-10-27
October 27, 2019 / BIOON / -- tumor immunotherapy giant BMS recently announced that the European Commission (EC) has approved two drug delivery schemes of PD-1 tumor immunotherapy opdivo (Chinese trad
-
Talking about tumor immunity to help precision medicine
Time of Update: 2019-10-26
In recent years, tumor immunotherapy, as a representative, has made a great breakthrough in tumor research and treatment Tumor immunotherapy is the fifth major therapy after surgery, radiotherapy, che
-
Nat commun: potential therapeutic target of PTEN mutation prostate cancer
Time of Update: 2019-10-26
October 26, 2019 / Biovalley BIOON / -- PTEN is a tumor suppressor gene, which mutates in about 20% of primary prostate cancer and up to 50% of castrated resistant prostate cancer PTEN relies on anoth
-
SCI Rep: use LAT1 to deliver drugs more effectively in the brain
Time of Update: 2019-10-25
October 25, 2019 / Biovalley BIOON / -- according to a new study by the University of East Finland, the highly expressed LAT1 in the brain can improve the distribution of drug molecules in the brain B
-
First line immunotherapy for head and neck cancer! Two schemes of kestruda were recommended and approved by the European Union for the treatment of PD-L1 positive patients
Time of Update: 2019-10-23
October 23, 2019 / BIOON / -- cancer immunotherapy giant Merck& CO) recently announced that the European Drug Administration (EMA) Committee on human medicinal products (CHMP) has issued a positive re
-
First line immunotherapy for lung cancer! The combination of bestimer opdivo with low dose yevoy and chemotherapy in phase III was successful, which significantly prolonged the overall survival period
Time of Update: 2019-10-23
October 23, 2019 / BIOON / -- BMS recently announced the results of critical phase III checkmate-9la test The trial is an open label, multicenter, randomized trial that is evaluating the first-line tr
-
Nat commun: Chinese scientists use new single cell genetic methods to solve potential drug resistance problems
Time of Update: 2019-10-23
October 23, 2019 / BIOON / -- researchers at the University of Notre Dame used a new technology that can identify the gene map of a single cell to simulate the potential resistance of breast cancer tu
-
First line treatment does not accord with the transplantation of multiple myeloma! Darzalex + Rd three drug scheme of Johnson & Johnson blood cancer drug won favorable review in EU
Time of Update: 2019-10-23
October 23, 2019 / bioun / -- Johnson & Johnson's Janssen Pharmaceutical recently announced that the European Drug Administration (EMA) human pharmaceutical products Committee (CHMP) has issued a posi
-
Lancet Oncol: immunotherapy drugs provide new treatment opportunities for patients who have previously received treatment for renal cancer and lung cancer
Time of Update: 2019-10-23
October 23, 2019 / Biovalley BIOON / -- pegilodecakin is a kind of drug currently undergoing clinical trials, which has shown positive safety results, and may provide a potential new treatment approac
-
Immunotherapy for metastatic Merkel cell carcinoma! Merck / Pfizer released bavencio's three-year data, with long-lasting efficacy and good safety!
Time of Update: 2019-10-23
October 23, 2019 / BIOON / -- Merck KGaA and Pfizer, partners, recently published the three-year results of the key phase II javelin Merkel 200 trial Part A, which involved the long-term total surviva
-
Major breakthrough in first-line treatment of liver cancer! Is this immune combination therapy expected to change the treatment mode?
Time of Update: 2019-10-22
Roche announced that tecentriq (atezolizumab, atzumab), a blockbuster PD-L1 inhibitor, combined with Avastin (bevacizumab), an anti VEGF antibody, reached two common primary endpoints in phase 3 clini
